by Impact Journals LLC Relations between aging and age-related diseases (ARDs). Credit: Aging (2023). DOI: 10.18632/aging.204920 A new research perspective titled “Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?” has been published in Aging. In his new research perspective, Dr. Mikhail V. Blagosklonny from Roswell Park Comprehensive Cancer Center discusses aging and rapamycin (Sirolimus)—the only drug...
IMPACT JOURNALS LLC IMAGE: FIGURE 2: RAPAMYCIN PREVENTS CANCER BY SLOWING TUMOR PROGRESSION (HYPOTHETICAL SCHEMA). CREDIT: 2023 BLAGOSKLONNY “[…] long-term treatment with rapamycin slows down aging, a major risk factor for cancer […]” BUFFALO, NY- April 17, 2023 – A new research perspective was published in Oncotarget’s Volume 14 on April 14, 2023, entitled, “Cancer prevention with rapamycin.” The mTOR (Target...
MAX PLANCK INSTITUTE FOR BIOLOGY OF AGEING IMAGE: RAPAMYCIN IS CURRENTLY THE MOST PROMISING ANTI-AGEING DRUG. CREDIT: MAX PLANCK INSTITUTE FOR BIOLOGY OF AGEING Imagine you could take a medicine that prevents the decline that come with age and keeps you healthy. Scientists are trying to find a drug that has these effects. The current...
EXPERIMENTAL BIOLOGY Rockville, Md. (April 27, 2021)–New research to be presented this week virtually at the American Physiological Society’s (APS) annual meeting at Experimental Biology 2021 explores the positive and negative effects of lifespan-extending drugs on mitochondrial function and age-related osteoarthritis (OA). Decreased function of mitochondria–the energy centers of the cells–is a hallmark characteristic of aging. Maintaining...
